Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock for approximately $121,000 on June 15, 2026, according to an SEC filing. The transaction was executed under a 10b5-1 trading plan adopted in December 2025 and reduced her direct holdings by 15% to 27,567 shares. The sale occurred against a backdrop of strong commercial performance, with first-quarter net product revenue for the ZORYVE franchise climbing 65% year over year to $105.4 million. Arcutis posted a narrower quarterly loss of $11.3 million and maintained full-year revenue guidance of $480 million to $495 million.
Arcutis Biotherapeutics IncStrong Q1 revenue growth and narrower loss, with maintained guidance, offsetting insider sale.